The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Third paragraph in the Chairman’s statement is the sexy stuff. How long before Exscientia lists ? When this happens along with the other portfolio advancements we should be in £2 per share territory
Great results.
I expect St to be positive about these on Monday so they will probably climb then.
"Frontier IP, an IP commercialisation company, has showed a strong FY’20 (period-end 30 June 2020) financial performance, in line with our cash flow expectations set out in our September note but make no changes at this juncture. Notably, net income from the unrealised revaluation of investments was up 55% to £6.0m, slightly ahead of our expectations of £5.8m. NAV/share grew 23% to 51.0p vs. 41.4p 30 June 2019, enjoying a 5 year CAGR of 19%. Results cap a fine period of news flow and portfolio progress has continued into FY’21 despite the ongoing COVID-19 pandemic, and we believe a number of companies are now at important inflection points in their development. Whilst COVID-19 has impacted portfolio companies differently, overall the portfolio continues to remain a net benefiter, chiefly driven by direct opportunities at The Vaccine Group, Elute Intelligence and Exscientia. The July fundraise of £2.2m (net) has significantly strengthened the balance sheet and management are well placed to execute its strategy to support portfolio progress and deploy additional capital via bridge financing if required."
I'm not an expert but these look like amazing results!!
Anyone know when final results due? Annual report is dated Nov so can’t be far off?
That 90-100 I would see as a short term target in the medium to long term it could be much higher.
Have to say I'm impressed with the management quality and how the company is adding value by bringing tried and tested investments into the portfolio. The individual companies are developed early in conjunction with industry and partners brought on board early on to give focus and direction to the companies thereby giving them a strong commercial footing from the start. Some of the portfolio companies are working with industry giants such as Bosch.
Many of the Investments are disruptive technologies including A.I., robotics, energy efficiency etc. I'm not a follower of Ark Invest's Catherine Wood but she is respected in the US. She has 5 platforms of disruptive innovations and 3 of these are:
Energy storage
Robotics
Artificial intelligence
Some of our investments cover these areas and through Pulsiv Solar energy efficiency.
Unlike Ark Invest which is fully valued, our investments are conservatively valued in the portfolio, for example the Exscientia stake could be worth the market cap alone.
Happy to hold medium to long term.
Thought I'd share a few simple thoughts as it is quiet here as mentioned already.
November for the next set of results? Based on your last year's date when they released their results. We just had one in April.
My target price is 90 to 100p.
we are not an active board but when you posted was 65p now 73p hope you bought
Potential new investor here, when are results due?
Lots of buys today and SP going up. Received my PrimaryBid shares yesterday and hoping to make a few quid....
Wonder why the funds are reducing - see recent RNS’s
Some meaty buys there.
Open after close of business and oversubscribed. My allocation scaled back by 30% so unlikely imo share price will fall back to placing price of 55p
What time did offer start i came across by chance at 6.30pm .
Closed within one hour ?
Same here. Offer now closed, response must be good.
I have taken part at 55p.
Seemed too cheap not to have a dabble.
10% up already just hit day high, i'm expecting others to catch on soon
Excellent RNS. Frontier IP are a good company, strong fundamentals.
Got in this morning, strong financials, strong growth and with the 21% in TVG along with other promising companies in their portfolio I will be here for some time
There was a lot of press a year ago that Exscientia would undergo an IPO on NASDAQ in May this year, with a suggested value of about $1bn. Does anyone know what appended to that planned float. I note that Exscientia have just raised 60m, so has the float been shelved or delayed?
Obviously the significance here is that Frontier hold 3.3%, which more than underpins current market cap.
Decided to get in yesterday. Period to June to be in line with expectations. Looking forward to run up through 80 pretty soon. ( fingers crossed. Lol )
Moreover, Frontier has announced a raft of positive news flow on other investee companies, too, all of which are highly supportive of the investment case. Rated on a modest 1.5 times conservative book value, and reflecting the fact that the value embedded in the Exscentia stake could ultimately be worth Frontier’s current market capitalisation of £33m, I am upgrading my target price from 80p to 100p. Buy.